INTRODUCTION: Spinal muscular atrophy (SMA) causes muscle weakness and fatigue. Better understanding of the relationship between weakness and fatigue may help identify potential targets for rehabilitation. METHODS: Gait and surface electromyography (EMG) from 4 muscle groups were measured during the Six-Minute Walk Test (6MWT) in 10 ambulatory participants, aged 9-49 years. Average root mean square amplitude (RMS) of muscle activity was calculated. Strength was assessed using manual and quantitative methods. RESULTS: RMS, stride length, and velocity decreased during the 6MWT. Knee flexor and hip abductor strength was associated with fatigue-related changes; overall strength correlated with disease duration; and leg strength was associated with 6MWT distance. CONCLUSIONS: Clinical measures are valid in assessing fatigue and function in SMA, and these assessments can be enhanced by use of gait analysis and EMG. Disease duration and strength measures may represent further stratification refinements when enrolling patients in clinical trials.
INTRODUCTION:Spinal muscular atrophy (SMA) causes muscle weakness and fatigue. Better understanding of the relationship between weakness and fatigue may help identify potential targets for rehabilitation. METHODS: Gait and surface electromyography (EMG) from 4 muscle groups were measured during the Six-Minute Walk Test (6MWT) in 10 ambulatory participants, aged 9-49 years. Average root mean square amplitude (RMS) of muscle activity was calculated. Strength was assessed using manual and quantitative methods. RESULTS: RMS, stride length, and velocity decreased during the 6MWT. Knee flexor and hip abductor strength was associated with fatigue-related changes; overall strength correlated with disease duration; and leg strength was associated with 6MWT distance. CONCLUSIONS: Clinical measures are valid in assessing fatigue and function in SMA, and these assessments can be enhanced by use of gait analysis and EMG. Disease duration and strength measures may represent further stratification refinements when enrolling patients in clinical trials.
Authors: Aga Lewelt; Kristin J Krosschell; Gregory J Stoddard; Cindy Weng; Mei Xue; Robin L Marcus; Eduard Gappmaier; Louis Viollet; Barbara A Johnson; Andrea T White; Donata Viazzo-Trussell; Philippe Lopes; Robert H Lane; John C Carey; Kathryn J Swoboda Journal: Muscle Nerve Date: 2015-10 Impact factor: 3.217
Authors: Jacqueline Montes; Michael P McDermott; Elizabeth Mirek; Elena S Mazzone; Marion Main; Allan M Glanzman; Tina Duong; Sally Dunaway Young; Rachel Salazar; Amy Pasternak; Richard Gee; Roberto De Sanctis; Giorgia Coratti; Nicola Forcina; Lavinia Fanelli; Danielle Ramsey; Evelin Milev; Matthew Civitello; Marika Pane; Maria Carmela Pera; Mariacristina Scoto; John W Day; Gihan Tennekoon; Richard S Finkel; Basil T Darras; Francesco Muntoni; Darryl C De Vivo; Eugenio Mercuri Journal: PLoS One Date: 2018-06-26 Impact factor: 3.240
Authors: Bart Bartels; Laura E Habets; Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Marja A G C Schoenmakers; Tim Takken; Erik H J Hulzebos; W Ludo van der Pol; Janke F de Groot Journal: BMC Neurol Date: 2019-02-09 Impact factor: 2.474
Authors: Jacqueline Montes; Sally Dunaway Young; Elena S Mazzone; Amy Pasternak; Allan M Glanzman; Richard S Finkel; Basil T Darras; Francesco Muntoni; Eugenio Mercuri; Darryl C De Vivo; Kathie M Bishop; Eugene Schneider; C Frank Bennett; Richard Foster; Wildon Farwell Journal: Muscle Nerve Date: 2019-07-27 Impact factor: 3.852
Authors: Laura E Habets; Bart Bartels; Fay-Lynn Asselman; Melissa T Hooijmans; Sandra van den Berg; Aart J Nederveen; W Ludo van der Pol; Jeroen A L Jeneson Journal: Brain Date: 2022-05-24 Impact factor: 15.255
Authors: Rafael Rodriguez-Torres; Julia Fabiano; Ashley Goodwin; Ashwini K Rao; Stacy Kinirons; Darryl De Vivo; Jacqueline Montes Journal: J Neuromuscul Dis Date: 2020